StreetInsider.com News Articles

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath’s percutaneous hepatic perfusion (PHP) with melphalan using the HEPZATO KIT™ Hepatic Delivery System (HDS) in metastatic melanoma involving the liver — a common and difficult-to-treat site of disease progression.

One abstract, titled

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

One abstract, titled

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

One abstract, titled

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

One abstract, titled

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

One abstract, titled

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

One abstract, titled

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

One abstract, titled

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Tue, 26 May 2026 16:01:00 -0400

One abstract, titled

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:01:00 -0400

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either March 2026 or April 2026.

The grants, in the form of Restricted Stock Units (RSUs), totaled 24,500 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The RSUs were granted on May 1,

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:01:00 -0400

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:01:00 -0400

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:01:00 -0400

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: Sylvester John Richard

Thu, 14 May 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260514/26496986.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: Sylvester John Richard

Thu, 14 May 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260514/26496986.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: Martell Bridget A

Thu, 14 May 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260514/26496975.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: Martell Bridget A

Thu, 14 May 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260514/26496975.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: CZEREPAK ELIZABETH

Thu, 14 May 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26496968.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: CZEREPAK ELIZABETH

Thu, 14 May 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26496968.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: Aharon Gil

Thu, 14 May 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26496969.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: Aharon Gil

Thu, 14 May 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26496969.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: SALAMON STEVEN A J

Thu, 14 May 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26496970.html

Form 4 DELCATH SYSTEMS, INC. For: May 13 Filed by: SALAMON STEVEN A J

Thu, 14 May 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260514/26496970.html

Form 8-K DELCATH SYSTEMS, INC. For: May 13

Thu, 14 May 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20260514/26490540.html

Form 8-K DELCATH SYSTEMS, INC. For: May 13

Thu, 14 May 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20260514/26490540.html

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Tue, 12 May 2026 08:00:00 -0400

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New York, NY.

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion